nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCB1—Parkinson's disease	0.534	1	CbGaD
Dabrafenib—NEK11—medulla oblongata—Parkinson's disease	0.00797	0.0737	CbGeAlD
Dabrafenib—RAF1—hindbrain—Parkinson's disease	0.00588	0.0543	CbGeAlD
Dabrafenib—NEK11—cerebellum—Parkinson's disease	0.00564	0.0521	CbGeAlD
Dabrafenib—LIMK1—midbrain—Parkinson's disease	0.00522	0.0482	CbGeAlD
Dabrafenib—NEK11—brain—Parkinson's disease	0.00458	0.0423	CbGeAlD
Dabrafenib—SIK1—forebrain—Parkinson's disease	0.00409	0.0377	CbGeAlD
Dabrafenib—LIMK1—cerebellum—Parkinson's disease	0.00404	0.0373	CbGeAlD
Dabrafenib—RAF1—embryo—Parkinson's disease	0.00368	0.034	CbGeAlD
Dabrafenib—RAF1—brainstem—Parkinson's disease	0.00337	0.0311	CbGeAlD
Dabrafenib—LIMK1—brain—Parkinson's disease	0.00328	0.0303	CbGeAlD
Dabrafenib—RAF1—forebrain—Parkinson's disease	0.00325	0.03	CbGeAlD
Dabrafenib—BRAF—midbrain—Parkinson's disease	0.00322	0.0298	CbGeAlD
Dabrafenib—SIK1—medulla oblongata—Parkinson's disease	0.00295	0.0273	CbGeAlD
Dabrafenib—RAF1—cardiovascular system—Parkinson's disease	0.00275	0.0254	CbGeAlD
Dabrafenib—SIK1—spinal cord—Parkinson's disease	0.00263	0.0243	CbGeAlD
Dabrafenib—BRAF—cerebellum—Parkinson's disease	0.00249	0.023	CbGeAlD
Dabrafenib—RAF1—medulla oblongata—Parkinson's disease	0.00235	0.0217	CbGeAlD
Dabrafenib—SIK1—head—Parkinson's disease	0.00234	0.0216	CbGeAlD
Dabrafenib—SIK1—nervous system—Parkinson's disease	0.00222	0.0205	CbGeAlD
Dabrafenib—RAF1—midbrain—Parkinson's disease	0.00215	0.0198	CbGeAlD
Dabrafenib—SIK1—central nervous system—Parkinson's disease	0.00214	0.0197	CbGeAlD
Dabrafenib—RAF1—spinal cord—Parkinson's disease	0.00209	0.0194	CbGeAlD
Dabrafenib—SIK1—cerebellum—Parkinson's disease	0.00209	0.0193	CbGeAlD
Dabrafenib—BRAF—brain—Parkinson's disease	0.00203	0.0187	CbGeAlD
Dabrafenib—RAF1—head—Parkinson's disease	0.00186	0.0172	CbGeAlD
Dabrafenib—RAF1—nervous system—Parkinson's disease	0.00177	0.0163	CbGeAlD
Dabrafenib—RAF1—central nervous system—Parkinson's disease	0.0017	0.0157	CbGeAlD
Dabrafenib—SIK1—brain—Parkinson's disease	0.0017	0.0157	CbGeAlD
Dabrafenib—RAF1—cerebellum—Parkinson's disease	0.00166	0.0153	CbGeAlD
Dabrafenib—RAF1—brain—Parkinson's disease	0.00135	0.0125	CbGeAlD
Dabrafenib—SLC22A6—brain—Parkinson's disease	0.00131	0.0121	CbGeAlD
Dabrafenib—SLC22A8—head—Parkinson's disease	0.00108	0.01	CbGeAlD
Dabrafenib—SLC22A8—nervous system—Parkinson's disease	0.00103	0.00948	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—Parkinson's disease	0.000988	0.00913	CbGeAlD
Dabrafenib—ABCG2—medulla oblongata—Parkinson's disease	0.000972	0.00898	CbGeAlD
Dabrafenib—ABCG2—midbrain—Parkinson's disease	0.000888	0.00821	CbGeAlD
Dabrafenib—ABCG2—spinal cord—Parkinson's disease	0.000867	0.00801	CbGeAlD
Dabrafenib—SLC22A8—brain—Parkinson's disease	0.000784	0.00725	CbGeAlD
Dabrafenib—ABCB1—embryo—Parkinson's disease	0.00075	0.00693	CbGeAlD
Dabrafenib—ABCG2—cerebellum—Parkinson's disease	0.000687	0.00635	CbGeAlD
Dabrafenib—ABCB1—forebrain—Parkinson's disease	0.000663	0.00613	CbGeAlD
Dabrafenib—CYP2C8—brain—Parkinson's disease	0.000574	0.0053	CbGeAlD
Dabrafenib—ABCB1—cardiovascular system—Parkinson's disease	0.000561	0.00518	CbGeAlD
Dabrafenib—ABCG2—brain—Parkinson's disease	0.000558	0.00516	CbGeAlD
Dabrafenib—CYP3A4—nervous system—Parkinson's disease	0.000509	0.0047	CbGeAlD
Dabrafenib—CYP3A4—central nervous system—Parkinson's disease	0.00049	0.00453	CbGeAlD
Dabrafenib—ABCB1—medulla oblongata—Parkinson's disease	0.000479	0.00443	CbGeAlD
Dabrafenib—ABCB1—midbrain—Parkinson's disease	0.000438	0.00405	CbGeAlD
Dabrafenib—ABCB1—spinal cord—Parkinson's disease	0.000427	0.00395	CbGeAlD
Dabrafenib—ABCB1—head—Parkinson's disease	0.00038	0.00351	CbGeAlD
Dabrafenib—ABCB1—nervous system—Parkinson's disease	0.00036	0.00333	CbGeAlD
Dabrafenib—ABCB1—central nervous system—Parkinson's disease	0.000347	0.0032	CbGeAlD
Dabrafenib—ABCB1—cerebellum—Parkinson's disease	0.000339	0.00313	CbGeAlD
Dabrafenib—ABCB1—brain—Parkinson's disease	0.000275	0.00254	CbGeAlD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	6.88e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PENK—Parkinson's disease	6.86e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAG—Parkinson's disease	6.86e-05	0.000192	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CTGF—Parkinson's disease	6.84e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—Parkinson's disease	6.83e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD3—Parkinson's disease	6.81e-05	0.00019	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	6.8e-05	0.00019	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—Parkinson's disease	6.79e-05	0.00019	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—Parkinson's disease	6.76e-05	0.000189	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—Parkinson's disease	6.74e-05	0.000188	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MCCC1—Parkinson's disease	6.74e-05	0.000188	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ND3—Parkinson's disease	6.74e-05	0.000188	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—INSR—Parkinson's disease	6.61e-05	0.000185	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	6.61e-05	0.000185	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GCH1—Parkinson's disease	6.57e-05	0.000184	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTA4—Parkinson's disease	6.54e-05	0.000183	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—Parkinson's disease	6.52e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—Parkinson's disease	6.49e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—Parkinson's disease	6.46e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—MAPK8—Parkinson's disease	6.45e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—Parkinson's disease	6.43e-05	0.00018	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—COMT—Parkinson's disease	6.4e-05	0.000179	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP2E1—Parkinson's disease	6.37e-05	0.000178	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	6.37e-05	0.000178	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PLA2G6—Parkinson's disease	6.36e-05	0.000178	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADRBK1—Parkinson's disease	6.36e-05	0.000178	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	6.35e-05	0.000177	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TALDO1—Parkinson's disease	6.33e-05	0.000177	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—OMD—Parkinson's disease	6.33e-05	0.000177	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	6.31e-05	0.000176	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NQO1—Parkinson's disease	6.3e-05	0.000176	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MAOB—Parkinson's disease	6.3e-05	0.000176	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	6.28e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDYN—Parkinson's disease	6.27e-05	0.000175	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CP—Parkinson's disease	6.26e-05	0.000175	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGB—Parkinson's disease	6.25e-05	0.000175	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR1A—Parkinson's disease	6.22e-05	0.000174	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TH—Parkinson's disease	6.21e-05	0.000173	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MAPK8—Parkinson's disease	6.19e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DRD2—Parkinson's disease	6.16e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR7—Parkinson's disease	6.16e-05	0.000172	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TAC1—Parkinson's disease	6.12e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—INS—Parkinson's disease	6.09e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—Parkinson's disease	6.05e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	6.05e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—Parkinson's disease	6.05e-05	0.000169	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD1—Parkinson's disease	6.01e-05	0.000168	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NDUFB11—Parkinson's disease	6e-05	0.000168	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	6e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—Parkinson's disease	5.99e-05	0.000167	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYCS—Parkinson's disease	5.96e-05	0.000167	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—Parkinson's disease	5.95e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—Parkinson's disease	5.94e-05	0.000166	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—Parkinson's disease	5.93e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—Parkinson's disease	5.91e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GFAP—Parkinson's disease	5.9e-05	0.000165	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLA2G6—Parkinson's disease	5.89e-05	0.000165	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GBA—Parkinson's disease	5.86e-05	0.000164	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DBH—Parkinson's disease	5.86e-05	0.000164	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—FBP1—Parkinson's disease	5.86e-05	0.000164	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	5.85e-05	0.000163	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MAOB—Parkinson's disease	5.83e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GRM5—Parkinson's disease	5.83e-05	0.000163	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD3—Parkinson's disease	5.82e-05	0.000162	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ADRBK1—Parkinson's disease	5.81e-05	0.000162	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	5.77e-05	0.000161	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCH1—Parkinson's disease	5.73e-05	0.00016	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADRBK1—Parkinson's disease	5.43e-05	0.000152	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ADRBK1—Parkinson's disease	5.37e-05	0.00015	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	5.36e-05	0.00015	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HSPA1A—Parkinson's disease	5.33e-05	0.000149	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—COMT—Parkinson's disease	5.28e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DRD2—Parkinson's disease	5.26e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR7—Parkinson's disease	5.26e-05	0.000147	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTP1—Parkinson's disease	5.26e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—Parkinson's disease	5.25e-05	0.000147	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MAOA—Parkinson's disease	5.24e-05	0.000146	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—HMOX1—Parkinson's disease	5.18e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	5.18e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF20—Parkinson's disease	5.11e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GBA—Parkinson's disease	5.1e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DBH—Parkinson's disease	5.1e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FBP1—Parkinson's disease	5.1e-05	0.000143	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ABCB1—Parkinson's disease	4.98e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADORA2A—Parkinson's disease	4.96e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EDN1—Parkinson's disease	4.93e-05	0.000138	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APOE—Parkinson's disease	4.89e-05	0.000137	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTM1—Parkinson's disease	4.83e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ABL1—Parkinson's disease	4.74e-05	0.000132	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP2D6—Parkinson's disease	4.68e-05	0.000131	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GPX1—Parkinson's disease	4.63e-05	0.000129	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CTGF—Parkinson's disease	4.6e-05	0.000128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INSR—Parkinson's disease	4.58e-05	0.000128	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	4.57e-05	0.000128	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	4.46e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HGF—Parkinson's disease	4.46e-05	0.000124	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF2—Parkinson's disease	4.41e-05	0.000123	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP2D6—Parkinson's disease	4.33e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGB—Parkinson's disease	4.33e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HTR2A—Parkinson's disease	4.32e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR1A—Parkinson's disease	4.3e-05	0.00012	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DDC—Parkinson's disease	4.3e-05	0.00012	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CYCS—Parkinson's disease	4.28e-05	0.00012	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP2E1—Parkinson's disease	4.28e-05	0.00012	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—Parkinson's disease	4.27e-05	0.000119	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1R—Parkinson's disease	4.26e-05	0.000119	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CTGF—Parkinson's disease	4.25e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TAC1—Parkinson's disease	4.24e-05	0.000118	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NQO1—Parkinson's disease	4.23e-05	0.000118	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EDN1—Parkinson's disease	4.21e-05	0.000118	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	4.2e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—Parkinson's disease	4.19e-05	0.000117	CbGpPWpGaD
Dabrafenib—BRAF—Disease—INS—Parkinson's disease	4.18e-05	0.000117	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TH—Parkinson's disease	4.17e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD1—Parkinson's disease	4.16e-05	0.000116	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ND3—Parkinson's disease	4.15e-05	0.000116	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MCCC1—Parkinson's disease	4.15e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—Parkinson's disease	4.12e-05	0.000115	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTA4—Parkinson's disease	4.06e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD3—Parkinson's disease	4.02e-05	0.000112	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	4.01e-05	0.000112	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYCS—Parkinson's disease	4.01e-05	0.000112	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—Parkinson's disease	3.97e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP2E1—Parkinson's disease	3.96e-05	0.000111	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—Parkinson's disease	3.96e-05	0.00011	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NQO1—Parkinson's disease	3.92e-05	0.000109	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.9e-05	0.000109	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—OMD—Parkinson's disease	3.9e-05	0.000109	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NGF—Parkinson's disease	3.87e-05	0.000108	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TH—Parkinson's disease	3.86e-05	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRBK1—Parkinson's disease	3.76e-05	0.000105	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DDC—Parkinson's disease	3.75e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—Parkinson's disease	3.73e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.72e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYCS—Parkinson's disease	3.71e-05	0.000104	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	3.7e-05	0.000103	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2A—Parkinson's disease	3.68e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK8—Parkinson's disease	3.68e-05	0.000103	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLA2G6—Parkinson's disease	3.66e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR7—Parkinson's disease	3.64e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DRD2—Parkinson's disease	3.64e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—Parkinson's disease	3.64e-05	0.000102	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MAOB—Parkinson's disease	3.62e-05	0.000101	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—COMT—Parkinson's disease	3.55e-05	9.91e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTA4—Parkinson's disease	3.54e-05	9.88e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTP1—Parkinson's disease	3.53e-05	9.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCH1—Parkinson's disease	3.53e-05	9.85e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MAOA—Parkinson's disease	3.52e-05	9.84e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HMOX1—Parkinson's disease	3.48e-05	9.73e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	3.44e-05	9.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—Parkinson's disease	3.43e-05	9.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—INS—Parkinson's disease	3.39e-05	9.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—Parkinson's disease	3.38e-05	9.45e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—Parkinson's disease	3.34e-05	9.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	3.32e-05	9.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—Parkinson's disease	3.3e-05	9.21e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—COMT—Parkinson's disease	3.29e-05	9.18e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—Parkinson's disease	3.27e-05	9.13e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MAOA—Parkinson's disease	3.26e-05	9.11e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—Parkinson's disease	3.25e-05	9.06e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—Parkinson's disease	3.22e-05	9.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLA2G6—Parkinson's disease	3.19e-05	8.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MAOB—Parkinson's disease	3.15e-05	8.81e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DBH—Parkinson's disease	3.14e-05	8.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FBP1—Parkinson's disease	3.14e-05	8.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GBA—Parkinson's disease	3.14e-05	8.78e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX1—Parkinson's disease	3.11e-05	8.68e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—Parkinson's disease	3.1e-05	8.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF2—Parkinson's disease	3.05e-05	8.52e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—Parkinson's disease	3e-05	8.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1R—Parkinson's disease	2.95e-05	8.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—INS—Parkinson's disease	2.93e-05	8.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDN1—Parkinson's disease	2.91e-05	8.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—INS—Parkinson's disease	2.89e-05	8.08e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX1—Parkinson's disease	2.88e-05	8.04e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—Parkinson's disease	2.87e-05	8.01e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	2.69e-05	7.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGF—Parkinson's disease	2.68e-05	7.48e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—Parkinson's disease	2.67e-05	7.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—Parkinson's disease	2.66e-05	7.43e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—Parkinson's disease	2.66e-05	7.42e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTGF—Parkinson's disease	2.64e-05	7.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—Parkinson's disease	2.55e-05	7.12e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—Parkinson's disease	2.47e-05	6.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	2.46e-05	6.87e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NQO1—Parkinson's disease	2.43e-05	6.8e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TH—Parkinson's disease	2.4e-05	6.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—Parkinson's disease	2.37e-05	6.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—Parkinson's disease	2.35e-05	6.56e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	2.34e-05	6.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—Parkinson's disease	2.34e-05	6.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DDC—Parkinson's disease	2.31e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYCS—Parkinson's disease	2.3e-05	6.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTGF—Parkinson's disease	2.3e-05	6.43e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INS—Parkinson's disease	2.28e-05	6.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	2.18e-05	6.09e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—Parkinson's disease	2.18e-05	6.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	2.14e-05	5.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—Parkinson's disease	2.14e-05	5.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—Parkinson's disease	2.12e-05	5.92e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INS—Parkinson's disease	2.11e-05	5.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TH—Parkinson's disease	2.09e-05	5.83e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—COMT—Parkinson's disease	2.04e-05	5.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—Parkinson's disease	2.03e-05	5.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INS—Parkinson's disease	2.02e-05	5.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MAOA—Parkinson's disease	2.02e-05	5.65e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYCS—Parkinson's disease	2.01e-05	5.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—Parkinson's disease	2e-05	5.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—Parkinson's disease	2e-05	5.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.96e-05	5.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.94e-05	5.43e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—Parkinson's disease	1.92e-05	5.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—Parkinson's disease	1.86e-05	5.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—Parkinson's disease	1.83e-05	5.1e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—Parkinson's disease	1.79e-05	4.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—COMT—Parkinson's disease	1.78e-05	4.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—Parkinson's disease	1.77e-05	4.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MAOA—Parkinson's disease	1.76e-05	4.93e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—Parkinson's disease	1.74e-05	4.87e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—Parkinson's disease	1.65e-05	4.6e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—Parkinson's disease	1.62e-05	4.54e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—Parkinson's disease	1.56e-05	4.35e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—Parkinson's disease	1.53e-05	4.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—Parkinson's disease	1.51e-05	4.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—Parkinson's disease	1.5e-05	4.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.44e-05	4.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.44e-05	4.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.42e-05	3.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—Parkinson's disease	1.39e-05	3.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—Parkinson's disease	1.37e-05	3.82e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—Parkinson's disease	1.34e-05	3.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.32e-05	3.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INS—Parkinson's disease	1.31e-05	3.66e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.31e-05	3.65e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TH—Parkinson's disease	1.29e-05	3.59e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—Parkinson's disease	1.28e-05	3.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—Parkinson's disease	1.26e-05	3.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.24e-05	3.45e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INS—Parkinson's disease	1.14e-05	3.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COMT—Parkinson's disease	1.09e-05	3.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	1.09e-05	3.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MAOA—Parkinson's disease	1.09e-05	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	1.07e-05	3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	1.03e-05	2.88e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	1e-05	2.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—Parkinson's disease	9.58e-06	2.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—Parkinson's disease	8.85e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	8.85e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—Parkinson's disease	8.23e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INS—Parkinson's disease	7.03e-06	1.96e-05	CbGpPWpGaD
